Instil Bio, Inc. (TIL) 10-Year Financial Performance & Capital Metrics

TIL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutInstil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.Show more

Revenue $0
EBITDA -$70M +54.7%
Net Income -$74M +52.5%
EPS (Diluted) -11.39 +52.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -37.51% +29.2%
ROIC -20.05% +41.0%
Debt/Equity 0.51 +34.6%
Interest Coverage -8.18 +73.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM0.12%

EPS CAGR

10Y-

5Y-

3Y-

TTM1.47%

ROCE

10Y Avg-41.11%

5Y Avg-32.99%

3Y Avg-35.97%

Latest-25.77%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	138K	0	0	0	0
Revenue Growth %	-	-	-1%	-	-	-
Cost of Goods Sold+	20K	0	0	5.99M	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-20K	138K	0	-5.99M	0	0
Gross Margin %	-	1%	-	-	-	-
Gross Profit Growth %	-	7.9%	-1%	-	1%	-
Operating Expenses+	6.58M	33.78M	155.56M	200.18M	159.17M	73.54M
OpEx % of Revenue	-	244.8%	-	-	-	-
Selling, General & Admin	2.56M	14.38M	51.31M	62.23M	47.55M	44.21M
SG&A % of Revenue	-	104.22%	-	-	-	-
Research & Development	4.03M	19.4M	107.25M	141.06M	39.6M	11.84M
R&D % of Revenue	-	140.57%	-	-	-	-
Other Operating Expenses	0	0	-3M	-3.11M	72.01M	17.49M
Operating Income+	-6.58M	-33.64M	-155.56M	-206.17M	-159.17M	-73.54M
Operating Margin %	-	-243.8%	-	-	-	-
Operating Income Growth %	-	-4.11%	-3.62%	-0.33%	0.23%	0.54%
EBITDA+	-6.57M	-33.39M	-152.81M	-200.18M	-154.41M	-69.93M
EBITDA Margin %	-	-241.94%	-	-	-	-
EBITDA Growth %	-	-4.09%	-3.58%	-0.31%	0.23%	0.55%
D&A (Non-Cash Add-back)	20K	256K	2.75M	5.99M	4.76M	3.61M
EBIT	-6.52M	-33.64M	-155.27M	-223.37M	-151.87M	-66.14M
Net Interest Income+	68K	70K	80K	1.77M	3.66M	-2M
Interest Income	68K	70K	80K	3.65M	8.87M	6.99M
Interest Expense	0	0	0	1.88M	5.21M	8.99M
Other Income/Expense	63K	-3.94M	-1.2M	-19.08M	3.08M	-594K
Pretax Income+	-6.52M	-37.59M	-156.75M	-225.25M	-156.09M	-74.14M
Pretax Margin %	-	-272.37%	-	-	-	-
Income Tax+	0	151K	39K	-2.07M	0	0
Effective Tax Rate %	0.99%	1%	1%	0.99%	1%	1%
Net Income+	-6.45M	-37.74M	-156.79M	-223.18M	-156.09M	-74.14M
Net Margin %	-	-273.46%	-	-	-	-
Net Income Growth %	-	-4.85%	-3.15%	-0.42%	0.3%	0.53%
Net Income (Continuing)	-6.52M	-37.74M	-156.79M	-223.18M	-156.09M	-74.14M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-1.01	-5.89	-29.60	-34.46	-24.00	-11.39
EPS Growth %	-	-4.83%	-4.03%	-0.16%	0.3%	0.53%
EPS (Basic)	-1.01	-5.89	-29.60	-34.46	-24.00	-11.39
Diluted Shares Outstanding	6.41M	6.41M	5.3M	6.48M	6.5M	6.51M
Basic Shares Outstanding	6.41M	6.41M	5.3M	6.48M	6.5M	6.51M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.29M	246.14M	464.02M	269.38M	160.76M	124.47M
Cash & Short-Term Investments	8.89M	241.71M	454.1M	260.92M	150.36M	113.31M
Cash Only	8.89M	241.71M	37.59M	43.72M	9.2M	8.8M
Short-Term Investments	0	0	416.51M	217.2M	141.16M	104.51M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	391K	0	0	8.46M	1.5M	1.83M
Total Non-Current Assets+	190K	72.87M	145.96M	212.75M	164.87M	139.1M
Property, Plant & Equipment	190K	55.34M	122M	209.34M	141.07M	130.34M
Fixed Asset Turnover	-	0.00x	-	-	-	-
Goodwill	0	5.72M	5.72M	0	0	0
Intangible Assets	0	10.1M	10.1M	0	0	0
Long-Term Investments	0	0	0	0	23.16M	0
Other Non-Current Assets	0	1.71M	8.14M	3.41M	639K	8.76M
Total Assets+	9.48M	319.01M	609.98M	482.13M	325.63M	263.57M
Asset Turnover	-	0.00x	-	-	-	-
Asset Growth %	-	32.67%	0.91%	-0.21%	-0.32%	-0.19%
Total Current Liabilities+	1.42M	13.28M	41.36M	32.79M	10.56M	7.9M
Accounts Payable	979K	3.5M	5.57M	2.36M	1.21M	659K
Days Payables Outstanding	17.87K	-	-	143.82	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	2.6M	13.65M	4.22M	1.22M	2.07M
Current Ratio	6.54x	18.53x	11.22x	8.22x	15.22x	15.76x
Quick Ratio	6.54x	18.53x	11.22x	8.22x	15.22x	15.76x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	13.36M	13.43M	85.73M	89.24M	86.23M
Long-Term Debt	0	0	0	72.35M	81.43M	84.19M
Capital Lease Obligations	0	0	0	5.17M	2.88M	1.02M
Deferred Tax Liabilities	0	0	2.43M	0	0	0
Other Non-Current Liabilities	0	13.36M	11M	8.21M	4.94M	1.03M
Total Liabilities	1.42M	26.64M	54.78M	118.52M	99.8M	94.13M
Total Debt+	0	0	0	79.9M	86.05M	86.89M
Net Debt	-8.89M	-241.71M	-37.59M	36.19M	76.86M	78.08M
Debt / Equity	-	-	-	0.22x	0.38x	0.51x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-109.49x	-30.56x	-8.18x
Total Equity+	8.06M	292.37M	555.2M	363.61M	225.83M	169.44M
Equity Growth %	-	35.29%	0.9%	-0.35%	-0.38%	-0.25%
Book Value per Share	1.26	45.61	104.76	56.15	34.72	26.03
Total Shareholders' Equity	8.06M	292.37M	555.2M	363.61M	225.83M	169.44M
Common Stock	0	0	0	0	0	0
Retained Earnings	-7.18M	-44.92M	-201.72M	-424.89M	-580.98M	-655.12M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	-283K	-87K	-493K	-348K	-228K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.29M	-29.62M	-122.14M	-180.16M	-82.03M	-55.7M
Operating CF Margin %	-	-214.61%	-	-	-	-
Operating CF Growth %	-	-4.6%	-3.12%	-0.48%	0.54%	0.32%
Net Income	-6.52M	-37.74M	-156.79M	-223.18M	-156.09M	-74.14M
Depreciation & Amortization	20K	256K	2.75M	5.99M	4.76M	3.61M
Stock-Based Compensation	293K	1.71M	26.2M	30.44M	18.17M	17.26M
Deferred Taxes	0	0	710K	0	0	0
Other Non-Cash Items	550K	4.68M	636K	16.15M	60.15M	10.18M
Working Capital Changes	366K	1.48M	4.36M	-9.57M	-9.02M	-12.61M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	309K	-1.05M	3.86M	-1.81M	-1.13M	-556K
Cash from Investing+	-760K	-51.12M	-474.4M	114.54M	41.13M	53.97M
Capital Expenditures	-210K	-50.82M	-57.83M	-84.59M	-20.66M	-10M
CapEx % of Revenue	-	368.23%	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-550K	0	0	-1.17M	1.56M	866K
Cash from Financing+	14.95M	313.05M	393.16M	71.89M	8.08M	1.75M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	430K	1.69M	0	0	-1.01M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-6.05M	-80.43M	-179.97M	-264.75M	-102.69M	-65.7M
FCF Margin %	-	-582.84%	-	-	-	-
FCF Growth %	-	-12.29%	-1.24%	-0.47%	0.61%	0.36%
FCF per Share	-0.94	-12.55	-33.96	-40.88	-15.79	-10.09
FCF Conversion (FCF/Net Income)	0.82x	0.78x	0.78x	0.81x	0.53x	0.75x
Interest Paid	0	0	0	0	0	8M
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-80.11%	-25.12%	-37%	-48.58%	-52.96%	-37.51%
Return on Invested Capital (ROIC)	-	-101.31%	-41.06%	-33.71%	-33.99%	-20.05%
Gross Margin	-	100%	-	-	-	-
Net Margin	-	-27346.38%	-	-	-	-
Debt / Equity	-	-	-	0.22x	0.38x	0.51x
Interest Coverage	-	-	-	-109.49x	-30.56x	-8.18x
FCF Conversion	0.82x	0.78x	0.78x	0.81x	0.53x	0.75x
Revenue Growth	-	-	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Instil Bio, Inc. (TIL) grew revenue by 0.0% over the past year. Growth has been modest.

Instil Bio, Inc. (TIL) reported a net loss of $75.1M for fiscal year 2024.

Dividend & Returns

Instil Bio, Inc. (TIL) has a return on equity (ROE) of -37.5%. Negative ROE indicates the company is unprofitable.

Instil Bio, Inc. (TIL) had negative free cash flow of $40.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener